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The ratio of S-adenosylmethione and S-adenosyl-homocysteine is increased in the 
brains of newborn rats in a model of valproic acid teratogenicity 
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The antiepileptic drug valproic acid (VPA) has a high teratogenic potential leading to 
major fetal malformations such as neurotubular defects. In addition to that children of 
women with epilepsy, exposed to valproate (VPA) in utero, show a significant 
decrease of intelligence and attention (Meador et al. 2009). Until now the 
mechanisms of the teratogenic effects of VPA are unclear.  
In their article “Multiple point action mechanism of valproic acid-teratogenicity 
alleviated by folic acid, vitamin C and N-acetylcysteine in chicken embryo model” 
Hsieh et al describe several possible mechanisms of VPA-induced teratogenicity, 
such as lowering the levels of homocysteine, folate, glutathione and induction of 
reactive oxygen species. In addition, they showed inhibition of two important 
enzymes of the homocysteine metabolism, that is dihydrofolate reductase and 
methylene folate reductase by VPA. 
  
In a rodent model of valproic acid teratogenicity we have found dose-dependent 
changes of S-adenosylmethione (SAM) and S-adenosyl-homocysteine (SAH) 
concentrations in the brains of newborn pups. Our results complement the data 
presented by Hsieh et al, who have not included SAM and SAH in their analysis.  
SAM and SAH occupy a central position in the homocysteine metabolism. SAM is an 
essential methyl donor to maintain normal methylation of DNA, RNA, proteins, and 
several other molecules for normal cell function and viability (Chiang et al. 1996; 
Ulrey et al. 2005). The degradation product of SAM is SAH, which is reversibly 
hydrolyzed to homocysteine. The transsulfuration of homocysteine finally leads to the 
production of glutathione. As an alternative to transsulfuration, Hcys can be recycled 
by remethylation via methionine synthase. This requires vitamin B12 and folate as 
co-factors.  
 
To induce VPA teratogenicity, we diluted valproate into the drinking water of female 
Wistar rats starting 7days before conception and during pregnancy. With drug 
concentrations of 3.3mg/ml (n=6), and 6.6 mg/ml (n=6), daily valproate dosages of 
about 470mg/kg (medium dosage (MD), and 720 mg/kg (high dosage (HD)) were 
reached. We have previously shown that this intrauterine VPA exposure leads to 
changes in activity and memory and changes in volume of different brain areas 
(Frisch et al. 2009).  
 
Newborn offspring (p1) with intrauterine VPA exposure and controls were perfused 
with a PBS – buffer, and brains were removed and stored at -80C. In brain lysates we 
performed simultaneous determination of SAM and SAH by using stable isotope 
dilution tandem mass spectrometry as previously published (Smith et al. 2006). 
 
There was a significant, dose-depended increase in the SAM/SAH ratio in brain 
tissues of VPA exposed animals.  
 
 Mean ± 
SD 
F p Bonferoni 
Controls 
 
MD 
 
HD 
Controls 7.88 9.56 0.002 - 0.162 0.002 
MD 10.44 0.162 - 0.113 
HD 13.24 0.002 0.113 - 
 
Table 1: SAM/SAH ratio in brain lysates of newborn pups (P1) 
 
 
These results further corroborate the findings of Hsieh et al and the assumption that 
disruption of folate and homocysteine metabolism is a possible teratogenic 
mechanism of VPA treatment. Because SAM and SAH are the substrate and product 
of essential methyltransferase reactions, and because SAH is an effective antagonist 
of transmethylation enzymes, the ratio of SAM/SAH is used as an indicator of the 
cellular methylation potential (Cantoni 1985; Hoffman et al. 1979). An increased 
methylation potential will influence numerous reactions involved in cellular 
metabolism, in particular DNA methylation (Detich et al. 2003; Rodenhiser and Mann 
2006), which is considered to be essential in neuronal cell differentiation (Singh et al. 
2009). The increase of the SAM/SAH ratio also leads to up-regulation of cystathionine 
beta-synthase (CBS) activity (Selhub and Miller 1992), which increases the flux of 
homocysteine through the transsulfuration pathway. CBS is additionally upregulated 
by production of reactive oxygen species (Singh et al. 2007), as measured by Hsieh 
et al. Both factors explain the observed decrease in homocysteine levels.
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